Jump to the top of the page

The Golden Team

 
William Blair Private Wealth Management

Members of the Golden Group

PWM Professional Resources

About William Blair

William Blair is a premier global boutique with expertise in investment banking, investment management, and private wealth management. We provide advisory services, strategies, and solutions to meet our clients’ evolving needs. As an independent and employee-owned firm, together with our strategic partners, we operate in more than 20 offices worldwide.*

  • 1935

    Year William Blair was founded

  • 1,900+

    Employees worldwide

  • 147 billion+

    Client assets

  • 90 Years

    Independent and employee-owned

  • 20+

    Offices worldwide

  • ~650

    Companies under coverage

As of December 31, 2024
*Includes strategic partnerships with Allier Capital, BDA Partners, and Poalim Capital Markets.

More about William Blair affiliated entities

Thought Leadership

  • The 2025 Tax Reference Guide

    William Blair's tax reference guide for income earned in 2025 and tax returns filed in 2026 is now available.

    Read more
  • Woman at a computer

    Risk: Understanding and Managing an Inevitable Part of Investing

    Identifying the various types of risk that investors face can help you think strategically about how to manage risk in a way that aligns with your goals and objectives.

    Read more
  • Financing a College Education: Options to Consider

    Tips for developing the best strategy while keeping your financial goals intact.

    Read more

Our Latest News

  • Rubrik, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Rubrik, Inc. (RBRK $75.59), a leading vendor in the fast-evolving data protection (DP) industry, pioneering a next-generation approach to data backup and transforming perceptions of DP technology from “boring old backup” to a must-have cyber resilience platform.

    Read more
  • Mersana Therapeutics, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Mersana Therapeutics, Inc. (MRSN $0.57), whose lead program emiltatug ledadotin is an ADC that targets B7-H4; it is in Phase I development for TNBC. The company is also developing a HER2-targeted immune-stimulating ADC, XMT-2056, in a Phase I solid tumor study.

    Read more
  • Odyssey Aviation U.S. Has Been Acquired by Tallvine Partners

    William Blair acted as the exclusive financial advisor to Odyssey Aviation U.S., a portfolio company of Equivu Capital and Granite Creek Capital Partners, in connection with its sale to Tallvine Partners.

    Read more

Ready to start a conversation? Contact us today.

This content is for informational and educational purposes only and not intended as investment advice or a recommendation to buy or sell any security. Investment advice and recommendations can be provided only after careful consideration of an investor's objectives, guidelines, and restrictions.

Copyright © 2025 William Blair & Company, L.L.C. | Privacy Terms

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures